Life Biosciences reports early safety data for glaucoma reprogramming drug

Life Biosciences announced that three glaucoma patients have received a single injection of its experimental cellular reprogramming drug with no serious adverse events. This is an early-stage safety readout; efficacy remains unproven. The development is notable as a first-in-human signal for a novel mechanism, but it is too early to assess therapeutic impact.